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Abstract
In the last years, guidelines for the treatment of hypertension recommended individualized blood pressure goals for geriatric
population because of elderly susceptibility to adverse outcomes and higher mortality rate deriving from the excessive blood
pressure lowering, especially in “frail” elderly. Recent findings from the SPRINT study, which demonstrated that intensive
blood pressure lowering was associated with lower rates of cardiovascular events and mortality in both hypertensive fit and
frail elderly subjects compared to standard treatment, heavily influenced the recent US guidelines. In SPRINT sub-study
analysis of adults aged ≥75 years, the most controversial issue appears the method of blood pressure measurement, the
selection of patients and related-frailty degree that appears to be very light. Accordingly, it has been described that light
frailty is related to good outcomes in older adults. SPRINT findings in “frail elderly patients” cannot be applied to the
clinical practice because this condition has been clearly under-estimated. Thus, frailty status should be routinely and
correctly quantified in order to identify the frailty degree and to find the best harms–benefits balance of antihypertensive drug
treatment in frail older adults.
Introduction
Age-related chronic diseases are largely prevalent in frail
elderly leading to polipharmacy and relative adverse out-
comes as well as severe functional limitation. Hypertension,
especially isolated systolic pattern, is a widespread condi-
tion in geriatric population, representing a well-established
risk factor for cardiovascular disease (CVD), chronic kidney
disease (CKD) and cognitive decline [1]. Based on several
trials [2–4] and meta-analysis, in the last years guidelines
for the treatment of hypertension recommended different
blood pressure (BP) goals for geriatric population compared
to young adults because of elderly susceptibility to adverse
outcomes deriving from the excessive BP lowering such as
falls, fractures, and cognitive impairment.
Most recently, the Systolic blood PRessure INtervention
Trial (SPRINT) [5], a large prospective study that compared
the effects of an intensive treatment of hypertension with a
standard one, has provided data showing a better outcome
in older adults treated with an aggressive antihypertensive
regimen: in a sub-group analysis of subjects aged >75 years,
the intensive treatment group had significantly lower rates
of CVD and mortality compared to participants receiving
* Pasquale Abete
p.abete@unina.it
1 Department of Translational Medical Sciences, University of
Naples “Federico II”, Naples, Italy
2 Istituti Clinici Scientifici Maugeri- Syncope unit - UOC Cure sub-
acute, Milan, Italy
3 Division of Internal Medicine, AOU San Giovanni di Dio e Ruggi
di Aragona, Salerno, Italy
4 Department of Medicine and Health Sciences, University of
Molise, Campobasso, Italy
5 Azienda Ospedaliero-Universitaria Careggi, University of
Florence, Florence, Italy
6 Azienda Ospedaliera dei Colli, Monaldi Hospital, Heart
Transplantation Unit, Naples, Italy
Electronic supplementary material The online version of this article
(https://doi.org/10.1038/s41371-018-0086-6) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
standard treatment [6]. The purpose of this review is to
critically analyze SPRINT Study’s results and BP goals in
elderly population based on the evidence available in
literature.
RCT and observational study in older
hypertensive subjects
In the last twenty years, several trials have observed posi-
tive effects in treating hypertension in older adults [2–4],
but no study aimed to reach a SBP target lower than
140 mmHg. On the contrary, clinical trials which achieved a
SBP lower than 140 mmHg showed no benefits in reaching
this goal [7, 8]. In the hypertension in the very elderly
trial (HYVET) [4], patients aged >80 years with
SBP >160 mmHg were randomized in two groups treated
with placebo or indapamide alone or in association with
perindopril. The results of this study showed that hyper-
tension treatment, based on indapamide with or without
perindopril aimed to achieve a target BP of 150/80 mmHg,
was associated with lower mortality rate. The Japanese trial
to assess optimal systolic blood pressure in elderly hyper-
tensive patients (JATOS) [7], evaluated the effect of
hypertension treatment with a SBP target <140 mmHg
compared to a SBP target among 140–160 mmHg, showing
no evidence of clinical benefit from aggressive BP lowering
compared with standard BP target in elderly aged >75
years. The results of this study confirmed that a strict BP
control may not enhance the clinical benefit in the preven-
tion of cardiovascular events as compared with that of
moderate BP control. Benetos et al. recently published the
results of the PARTAGE Study, (predictive values of blood
pressure and arterial stiffness in institutionalized very aged
population), a multicenter, observational study investigating
the relationship among mortality rate, SBP levels and
number of antihypertensive drugs (AHDs) in the elderly [9].
In a sample of 1130 frail older adults aged >80 years, living
in nursing homes, the study compared the subjects with a
SBP <130 mmHg receiving a combination of AHDs with all
other participants. Their results showed that, among very
old frail institutionalized subjects, the sub-group with lower
SBP (<130 mmHg), receiving an association of different
AHDs, had a doubled risk of mortality [9].
In The Singapore Chinese Health Study [10], Koh et al.
investigated the association between SBP categories and
CVD mortality among middle-aged and elderly adults with
and without CVD history. Data obtained provided evidence
that SBP between 120 and 139 mmHg values were asso-
ciated with the lowest risk of CVD mortality in middle aged
and elderly adults, regardless of underlying CVD. More
importantly, a higher rate of events above and below this
BP range were observed [10].
Guidelines pre-SPRINT
Over time, several guidelines suggested different BP targets
(Table 1). In 2013, the European society of hypertension/
European society of cardiology recommended a BP target
<140/90 mmHg and a SBP goal between 140 and
150 mmHg for elderly aged >80 years [11]. In the same
year, Eighth Joint National Committee (JNC 8) guidelines
recommended a target BP <150/90 mmHg in older adults
without diabetes mellitus or CKD and <140/90 mmHg in
the presence of these two conditions [12]. In the 2014
American society of hypertension guidelines identified the
threshold for treatment at SBP values <150 mmHg in sub-
jects aged >80 years [13]. In 2015, both “American college
of cardiology foundation/American heart association (ACC/
AHA)” and “Canadian hypertension education program
(CHEP)” recommended BP values <140/90 mmHg, and
>150/90 mmHg for octogenarians if tolerated [14].
Results of the SPRINT sub-study in the
elderly
The SPRINT Study [5] compared an intensive
(SBP < 120 mmHg) to a standard (SBP < 140 mmHg)
Table 1 Different BP goals
recommended by international
guidelines related to
hypertensive subjects cluster in
pre-SPRINT era
BP goal ESH/ESC
(2013) [13]
JNC-8
(2014) [14]
ASH/ISH
(2014) [15]
AHA/ACC
(2015) [16]
CHEP
(2017) [25]
AHA/ACC
(2017) [26]
Age <60 <140/90 <140/90 <140/90 <140/90 <140/90 <130/80
Age 60–79 <140/90 <150/90 <140/90 <140/90 <140/90 <130/80
Age >80 <150/90 <150/90 <150/90 <150/90 <140/90 <130/80
Diabetes <140/85 <140/90 <140/90 <140/90 <130/80 <130/80
CKD <130/90 <140/90 <140/90 <140/90 <140/90 <130/80
ESC European society of cardiology; ESH European society of hypertension; JNC-8 eighth joint national
committee; ASH American society of hypertension; ISH international society of hypertension; AHA
American heart association; ACC American college of cardiology; CHEP Canadian hypertension education
program; CKD chronic kidney disease; BP blood pressure
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treatment regimen. In a sub-group analysis of the 2636
participants aged 75 years or older [6], intensive treatment
was associated to a reduction in primary composite end-
point of myocardial infarction, other acute coronary syn-
dromes, stroke, heart failure, or cardiovascular death by
34% and all-cause mortality by 33% after a median follow-
up of 3.14 years. At the same time, adverse events
rate (hypotension, syncope, acute kidney injury, and elec-
trolyte abnormalities was not significantly higher compared
to the standard group. A positive aspect of this trial
is represented by the large sample of elderly ≥75 years
(28.2% in each group) in study population. On the other
hand, the exclusion of institutionalized adults and of sub-
jects with a history of stroke, diabetes, or recent CVD
symptoms, represents a strong limitation for SPRINT results
application in clinical practice. In addition, the absence of
attending physician, usually present during BP measure-
ment in all other trial and in clinical practice, could have
reduced the “white coat” effect that increase BP averages
about 20/10 mmHg after the doctor’s/nurse’s arrival [15],
resulting in lower pressure values and making SPRINT data
incomparable to other trials [16]. In the intensive treatment
arm there was a greater use of diuretics, which may have
masked the symptoms of heart failure rather than preventing
them, and therefore, SPRINT results may have been unre-
lated to the difference BP reduction [17]. Mean SBP in
intensive group was 123.4 mmHg, and consequently, a
large part of elderly had a SBP out of target for the intensive
treatment group (<120 mmHg). In intensive arm more
medications were needed (mean 2.8 vs. 1.8) to reach the
SBP target although the use of multiple AHDs frequently
lead to serious adverse events in elderly (i.e. orthostatic
hypotension, dizziness, falls, syncope, and electrolyte
abnormalities [18]. Finally, about 30% of intensive group
patients were seen for unscheduled clinic visits, probably
leading to a more accurate treatment in this arm and having
more opportunity to report adverse effects [19].
Guidelines post-SPRINT
BP targets recommended for hypertension management in
older adults are discordant in light of new evidence shown
by SPRINT Study (Fig. 1). In 2017, The American college
of physicians and the American academy of family physi-
cians recommended a traditional approach in adults aged
>60 years with a SBP goal <150 mmHg or <140 mmHg in
patients with history of stroke or transient ischemic attack or
with a high cardiovascular risk [20].
In the same year, Canadian guidelines for diagnosis, risk
assessment, prevention, and treatment of hypertension in
adults [21] did not recommend different approach for older
adults, without a caution about frailty. The recent ACC/AHA
hypertension guidelines for the prevention, detection, eva-
luation, and management of high blood pressure in adults
recommend “SBP treatment goal of less than 130mmHg for
non-institutionalized ambulatory community-dwelling adults
(≥65 years of age) with an average SBP of 130mm Hg
or higher” (I-A recommendation), clearly based on SPRINT
results.
In a lower degree recommendation (II-C), they suggest
that “for older adults with high burden of comorbidity and
limited life expectancy, clinical judgment, patient pre-
ference, and a team-based approach to assess risk/benefit is
reasonable for decisions regarding intensity of BP lowering
and choice of antihypertensive drugs”. These recommen-
dations seem to be far from a real-life elderly patient, often
institutionalized and with high degree of comorbidity. [22]
Thus, the therapeutic approach for these complex kind of
patients is not clear and seems at least questionable as so
strong recommendation based mainly on a single trial with a
great deal of light and shade.
Frailty and BP targets
Frailty is considered as a geriatric dynamic condition
characterized by an increased vulnerability to external
stressors, by a multi-system dysfunction, by a complex
etiology and by an intrinsic difficulty in distinguishing from
aging [23]. Fried et al. defined frailty as a phenotype
characterized by three or more of the following: uninten-
tional weight loss of 10 lbs or more in the past year, self-
reported exhaustion, weakness measured by grip strength,
slow walking speed, and low physical activity [24],
describing only the physical domain of this condition. In
contrast, Rockwood et al. consider frailty as a “clinical”
Fig. 1 Blood pressure (BP) target in hypertensive older adults
recommended by guidelines from pre- to post-SPRINT era (AHA
American heart association; ACC American college of cardiology;
ESC European society of cardiology; JNC-8 eighth joint national
committee; ASH American society of hypertension; SPRINT systolic
blood pressure intervention trial; CHEP Canadian hypertension edu-
cation program; ACP American college of physicians; AAFP Amer-
ican academy of family physicians)
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condition and characterized by comorbidity, polypharmacy
and relative adverse drug reactions, age-associated sensory
deficits and lack of social support and high risk of disability,
hospitalization, and health services utilization (multi-
dimensional phenotype) [25].
Identifying older adults with a high frailty degree is
extremely important in order to prevent aggressive drug
regimens, to guarantee a safer approach and to improve
quality of life [26]. There are few data on hypertension in
the frail elderly. Post hoc analyses of SPRINT [6] and
HYVET [27] trials suggest that frailty condition does
not influence treatment effects on hypertensive subjects
[28, 29]. In fact, most trials in older adults did not assess
frailty or exclude patients with moderate-severe degree of
frailty.
In 2015, Ogliari et al. [30] investigated the relationship
between BP and mortality in older adults according to age,
functional and cognitive status. SBP higher than 165 mmHg
(but lower than 180 mmHg) and DBP higher than 85 mmHg
were associated with the lowest mortality in patients with
impaired Activity daily living (ADL) and Mini mental state
examination (MMSE) but not in those with preserved ADL
and/or MMSE. These data prospect a personalized BP
management in older adults using functional and cognitive
status as markers of biological age [30]. A recent cohort
study investigated the role of office and ambulatory blood
pressure monitoring AHDs in predicting cognitive decline
progression in patients with dementia or mild cognitive
impairment (MCI) [31]. The authors showed an indepen-
dent association between low daytime SBP and a greater
progression of cognitive decline in older patients with
dementia and mild cognitive impairment (MCI) among
those treated with AHDs [31]. In 2016, a meta-analysis
about the pressure treatment in older adults, collecting data
from large trial including elderly [28], confirmed that a BP
goal <150/90 mmHg improved outcomes such as mortality,
CVD, stroke, CKD and cognitive decline. However, in this
meta-analysis, the results supporting the positive effects of
an intensive antihypertensive therapy in the elderly were
largely deriving from SPRINT Trial [28].
In SPRINT Study thfe frailty status of participants was
quantified using a 37-item frailty index (FI) and then sub-
jects were classified as fit (FI < 0.10), less fit (0.10 < FI <
0.21), or frail (FI > 0.21) [8]. In the exploratory sub-group
analysis on subjects aged >75 years, a large part of popu-
lation (30.9% out of 2636) were classified as “frail”. The
authors indicated that benefits of intensive BP control were
consistent among persons in this age range who were frail
or had reduced gait speed [8]. Therefore, the study sub-
group concluded that SPRINT Study “can successfully
recruit a heterogeneous sample of non-institutionalized
older adults” and that “these results also provide a future
basis to evaluate the effect of lower BP targets on
cardiovascular events and mortality according to frailty
status” [32].
However, these sentences appear questionable if we
analyze the frailty degree of patients observed in SPRINT
population. Frailty was defined by a FI > 0.21 (>7 items
lost) and the median of FI in intensive treatment group was
0.18 (0.13–0.23) that corresponds to a loss of 7(±2) items
and the median of FI in the standard treatment group was
0.17 (0.12–0.22), a loss of 6(±2) items. This means that the
highest frailty degree observed in the sub-group study was
equal to 0.23, corresponding to a loss of 9/37 items. In
2017, an Italian version of Frailty Index [33] (IFi) of 40
items was validated in a cohort of 1077 non-disabled out-
patients aged 65 years or older (81.3 ± 6.5 years). Frailty
degree was stratified in light, moderate and severe accord-
ing to IFi scores obtained. Mortality, disability (≥1 ADL
lost from the baseline) and hospitalization were considered
at 3, 6, 12, 18 and 24 months of follow-up. In the light
frailty group, the items lost were 10.3 ± 4.5/40 items and
these participants had significant lower mortality rate
compared to moderate and severe frailty group (Fig. 2).
These subjects with a “light” frailty degree are similar to
those considered “frail” by SPRINT study because of a loss
of only 9 items. It is clear that SPRINT sub-study excluded
moderate/severe frail elderly patients, making its conclu-
sions nor applicable in the “real world”. Thus, BP values
associated with peculiar characteristics of severe frailty as
the low body mass index and low serum total cholesterol,
are clearly related to higher mortality in the elderly [34, 35].
Conclusions
The management of hypertension in the elderly is con-
troversial. Several evidences suggest a SBP reduction not
exceeding 140 mmHg for its negative impact on elderly
population. However, the SPRINT study seems to establish
a positive effect of SBP reduction below 120 mmHg even in
subjects ≥75 years old although several methodological
Fig. 2 Mortality rate in older adults stratified by Italian version of
frailty index and its relation with frailty-related SPRINT analysis
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problems make questionable the SPRINT results, including
the exclusion of institutionalized adults, the automatic BP
measuring in the absence of attending physician, the greater
use of diuretics. In the elderly sub-study of SPRINT the
most controversial issue is the selection of patients and the
frailty degree evaluation that appears to be very light.
We conclude that SPRINT results can be applied only to
general population but not in “frail” elderly patients. Spe-
cifically, frailty status should be not only identified but also
well differentiated in different degree of frailty that might
significantly influence the antihypertensive therapy in the
elderly. Therefore, further prospective studies are required
to define a safe BP target tailored specifically in different
frailty degree.
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